Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure

Abstract Aims Dapagliflozin (DAPA), a sodium‐glucose co‐transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therap...

Descripció completa

Dades bibliogràfiques

Autors principals:	Shodai Kawanami, Yasuyuki Egami, Masaru Abe, Mizuki Osuga, Hiroaki Nohara, Kohei Ukita, Akito Kawamura, Koji Yasumoto, Naotaka Okamoto, Yasuharu Matsunaga‐Lee, Masamichi Yano, Masami Nishino
Format:	Artigo
Idioma:	Inglês
Publicat:	Oxford University Press 2025-06-01
Col·lecció:	ESC Heart Failure
Matèries:	acute decompensated heart failure dapagliflozin diuretics worsening renal function
Accés en línia:	https://doi.org/10.1002/ehf2.15212
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!